#1 Clinical Trials Search in Europe

Dorzolamide

This article examines the use of dorzolamide, a carbonic anhydrase inhibitor, in various clinical trials for eye disorders. Dorzolamide is commonly used to treat conditions like glaucoma and ocular hypertension by reducing intraocular pressure. The trials discussed here investigate its efficacy and safety, often in combination with other medications, for treating different eye conditions.

Table of Contents

What is Dorzolamide?

Dorzolamide is a medication primarily used to treat various eye conditions, particularly those related to increased pressure within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors[1]. Dorzolamide is often marketed under brand names such as Trusopt[1] or Dorzol[1]. This medication is typically available as eye drops and is used to lower intraocular pressure (IOP), which is the fluid pressure inside the eye[2].

Conditions Treated by Dorzolamide

Dorzolamide is used to treat several eye conditions, including:

  • Open-Angle Glaucoma: This is the most common form of glaucoma, where the drainage channels in the eye become clogged over time, leading to increased eye pressure[3].
  • Ocular Hypertension: A condition where the pressure inside the eye is higher than normal, but not yet high enough to be diagnosed as glaucoma[3].
  • Normal Tension Glaucoma: A type of glaucoma where eye pressure is within the normal range, but optic nerve damage still occurs[2].
  • Retinal Degenerations: Some studies have explored the use of dorzolamide in treating certain retinal conditions, particularly those involving fluid accumulation in the retina[4].

How Dorzolamide Works

Dorzolamide works by reducing the production of fluid (aqueous humor) within the eye. It does this by inhibiting an enzyme called carbonic anhydrase. By decreasing fluid production, dorzolamide helps to lower the pressure inside the eye[1]. This reduction in pressure is crucial for preventing damage to the optic nerve, which can lead to vision loss in conditions like glaucoma.

How Dorzolamide is Administered

Dorzolamide is typically administered as eye drops. The usual dosage is one drop in the affected eye(s) two or three times daily[1]. However, the exact dosage and frequency may vary depending on the specific condition being treated and the patient’s response to the medication. It’s important to follow your doctor’s instructions carefully when using dorzolamide.

Combination Therapies with Dorzolamide

Dorzolamide is often used in combination with other medications to enhance its effectiveness in lowering eye pressure. Common combinations include:

  • Dorzolamide-Timolol: This combination, often marketed as Cosopt, combines dorzolamide with timolol, a beta-blocker. It’s frequently used as a first-line treatment for glaucoma and ocular hypertension[5].
  • Dorzolamide with Prostaglandin Analogues: In some cases, dorzolamide may be used alongside prostaglandin analogues like latanoprost for enhanced pressure-lowering effects[6].

Efficacy of Dorzolamide

Clinical trials have demonstrated the effectiveness of dorzolamide in lowering intraocular pressure. For example:

  • A study on normal tension glaucoma showed that dorzolamide-timolol combination therapy significantly reduced IOP after 12 weeks of treatment[2].
  • Another study found that dorzolamide was effective in reducing macular fluid in patients with certain retinal degenerations[4].

The efficacy of dorzolamide can vary among individuals, and your doctor will monitor your response to the medication to ensure it’s working effectively for you.

Potential Side Effects

While dorzolamide is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Eye irritation or burning
  • Blurred vision
  • Bitter taste in the mouth
  • Allergic reactions (in rare cases)[1]

If you experience any persistent or severe side effects, it’s important to contact your healthcare provider.

Ongoing Research and Future Prospects

Researchers continue to explore new applications and formulations of dorzolamide. Some areas of ongoing research include:

  • Use of dorzolamide in combination with other medications for enhanced efficacy[3].
  • Exploring the potential of dorzolamide in treating macular edema associated with retinal diseases[7].
  • Investigating the effects of dorzolamide on retinal blood flow in diabetic retinopathy[6].

These ongoing studies may lead to new treatment strategies and expanded uses for dorzolamide in the future.

Aspect Details
Primary Use Reducing intraocular pressure in glaucoma and ocular hypertension
Administration Eye drops, typically 2-3 times daily
Conditions Studied Open-angle glaucoma, ocular hypertension, diabetic retinopathy, cystoid macular edema
Combination Therapies Often studied with timolol for potentially enhanced efficacy
Outcome Measures Intraocular pressure changes, visual acuity, retinal thickness, patient satisfaction
Study Designs Randomized controlled trials, comparative studies, open-label studies
Patient Populations Adults with various eye disorders, including some pediatric studies
Safety Assessments Monitoring for adverse events, changes in corneal thickness, patient tolerability

FAQ

  • What is dorzolamide used for in eye care? Dorzolamide is primarily used to reduce intraocular pressure in conditions like glaucoma and ocular hypertension. It works by decreasing the production of fluid inside the eye.
  • How is dorzolamide typically administered? Dorzolamide is usually administered as eye drops. In the clinical trials, it was often used 2-3 times daily, either alone or in combination with other medications like timolol.
  • What conditions are being studied using dorzolamide? The clinical trials are investigating dorzolamide for various eye conditions including open-angle glaucoma, ocular hypertension, diabetic retinopathy, and cystoid macular edema in patients with retinal degeneration.
  • Are there any side effects associated with dorzolamide use? While specific side effects weren't detailed in the trial summaries, eye medications can sometimes cause effects like eye irritation, blurred vision, or changes in taste sensation. The trials aim to assess both efficacy and safety of dorzolamide.
  • Is dorzolamide being studied in combination with other medications? Yes, several trials are studying dorzolamide in combination with other medications, particularly timolol. These combination therapies are being evaluated for their potential to provide better intraocular pressure control than single medications alone.

Ongoing Clinical Trials on Dorzolamide

  • Study on the Safety and Effectiveness of AGTC-501 for Men with X-linked Retinitis Pigmentosa

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Intraocular Pressure (IOP): The fluid pressure inside the eye. Elevated IOP is a major risk factor for glaucoma and can damage the optic nerve.
  • Glaucoma: A group of eye conditions that damage the optic nerve, often due to abnormally high pressure in the eye.
  • Ocular Hypertension: Elevated pressure within the eye without detectable changes in vision or damage to the eye structure.
  • Carbonic Anhydrase Inhibitor: A type of medication that reduces the production of fluid inside the eye, thereby lowering intraocular pressure.
  • Retinal Degeneration: A group of eye disorders that involve breakdown of cells in the retina, which can lead to vision loss.
  • Cystoid Macular Edema: A condition where fluid collects in the macula (central part of the retina), causing swelling that can affect vision.
  • Diabetic Retinopathy: A complication of diabetes that affects the blood vessels in the retina, potentially leading to vision problems.
  • Optical Coherence Tomography (OCT): A non-invasive imaging test that uses light waves to take cross-section pictures of the retina.
  • Visual Acuity: The clarity or sharpness of vision, often measured using an eye chart.
  • Tonometry: A test to measure the pressure inside the eye, used in diagnosing and monitoring glaucoma.

References

  1. https://clinicaltrials.gov/study/NCT05973305
  2. https://clinicaltrials.gov/study/NCT00832377
  3. https://clinicaltrials.gov/study/NCT05857267
  4. https://clinicaltrials.gov/study/NCT00716586
  5. https://clinicaltrials.gov/study/NCT00546286
  6. https://clinicaltrials.gov/study/NCT00619034
  7. https://clinicaltrials.gov/study/NCT02571972